Pharmaceutical segment is projected to dominate the Microbiological testing of water market
According to MarketsandMarkets, the microbiological testing of water market size is estimated to be valued at USD 1.6 billion in 2022 and is projected to reach USD 2.3 billion by 2027, recording a CAGR of 7.4% in terms of value. The industry is witnessing a lot of new product launches and collaborations and mergers between big players.
The Pharmaceutical segment is projected to dominate the Microbiological testing of water market and is projected to achieve the largest market share during the forecast period.
Pharmaceutical research is an important industrial segment for microbiological water testing. Identification of novel organisms in water that are employed in drug development is one of the major applications. Microbiological water quality monitoring is significant for the pharmaceutical and biopharma business because of this important application of drug development.
Pathogen-free water is a significant factor during the manufacture and research of various pharmaceutical products. The microbiological parameter is important in industry together with other water testing parameters since it can cause harmful microbiological effects and waterborne outbreaks when contaminated water is used. Microbiological water testing is required by stringent regulatory requirements and GMP (Good Manufacturing Practices) compliance to prevent health issues.
The key players in this market are 3M (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Döhler Group (Germany), Agilent Technologies, Inc. (US), Shimadzu Corporation (Japan), Merck (Germany), PerkinElmer, Inc. (US), Bio-Rad Laboratories, Inc. (US), IDEXX Laboratories, Inc. (US), Avantor Inc. (US), Hardy Diagnostics (US), LaMotte Company (US), Accepta Ltd (UK), and General Laboratory Products (US).
Comments
Post a Comment